Researchers at the Keck School of Medicine at the University of Southern California (USC) have discovered a drug compound, R805/CX-011, with the potential to alleviate the painful hyperinflammation from osteoarthritis. The findings concerning the prospective osteoarthritis treatment breakthrough, published in Science Translational Medicine, showed positive effects in animal models and could pave the way for…
FDA authorization of vilobelimab signals new opportunities for drug developers in inflammatory diseases
The FDA has granted InflaRx (Nasdaq:IFRX) emergency use authorization (EUA) for the monoclonal antibody Gohibic (vilobelimab) to treat critically-ill COVID-19 patients. The company’s shares were up yesterday almost 84% to $3.77. Today, its shares jumped an additional 62% to $6.10. The EUA represents a significant advance for the Jena, Germany–based company, which on March 31,…
Stelara shows promise for long-term management of ulcerative colitis
Janssen’s (NYSE:JNJ) Stelara supported corticosteroid-free remission in about half of ulcerative colitis patients in a 152-week long-term extension UNIFI study. At the end of the nearly three-year study, 55.2% of volunteers were in symptomatic remission. Of those patients, 96.4% were corticosteroid-free at week 152. Janssen, which is part of Johnson & Johnson, presented the data…